FLT3 and acute myeloid leukemia: Sorafenib is an oral multi-kinase inhibitor targeting not only FLT3 but also vascular endothelial growth factor (VEGF) receptors, c-Kit and platelet-derived growth factor (PDGF) receptors, all of which are expressed on AML and bone marrow stromal cells [6–9].